Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Aged
Antigens, CD20
/ metabolism
B-Lymphocytes
/ immunology
Carcinoma, Pancreatic Ductal
/ immunology
Female
Follow-Up Studies
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Pancreatectomy
/ mortality
Pancreatic Neoplasms
/ immunology
Prognosis
Survival Rate
Tumor Microenvironment
/ immunology
B-cell aggregates
B-cells
CD20
pancreatic ductal adenocarcinoma
survival
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Mar 2020
05 Mar 2020
Historique:
received:
30
01
2020
revised:
20
02
2020
accepted:
03
03
2020
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Patients with pancreatic ductal adenocarcinoma (PDAC) normally have a poor long-term prognosis. However, some rare cases of long-term survivors have been reported. The tumor microenvironment, consisting of cellular and stromal components, possibly plays an important role and might influence prognosis. In this context, the role of tumor-infiltrating B-cells and its impact on the survival in patients with PDAC remains controversial. We therefore aimed to assess the prognostic value of CD20-positive B-cells and CD20-positive B-cell aggregates as well as CD138, IgM, Pax5, and Ki67 on the survival of patients with PDAC using immunohistochemistry of FFPE pancreatectomy tissue sections from patients that underwent primary surgery for pT3- and R0-pancreatic adenocarcinoma between 1995 and 2016. Patients with PDAC were matched and grouped in 16 long-term-survivors (LTS, median overall survival (OS): 96 months [range: 61-177 months]) and 16 short-term-survivors (STS, median OS: 16 months [range: 7-32 months]). CD20-positive B-cells and B-cell aggregates in the tumor infiltration zone were significantly upregulated in the LTS-group compared to the STS-group (
Identifiants
pubmed: 32150869
pii: ijms21051779
doi: 10.3390/ijms21051779
pmc: PMC7084265
pii:
doi:
Substances chimiques
Antigens, CD20
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Discov. 2016 Mar;6(3):256-69
pubmed: 26715642
Oncogene. 2014 Jun 5;33(23):2956-67
pubmed: 23851493
Exp Cell Res. 2013 Jul 1;319(11):1644-9
pubmed: 23499742
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Oncoimmunology. 2015 Sep 11;5(4):e1085147
pubmed: 27141376
Pancreas. 2018 Sep;47(8):958-966
pubmed: 30074526
Ann Surg. 2018 Mar;267(3):411-417
pubmed: 28379871
BMC Cancer. 2013 Sep 24;13:436
pubmed: 24063854
Curr Top Microbiol Immunol. 1996;210:167-79
pubmed: 8565555
J Clin Pathol. 2009 Dec;62(12):1117-22
pubmed: 19946098
Surgery. 2016 Jun;159(6):1520-1527
pubmed: 26847803
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Immunol. 1985 Dec;135(6):3795-801
pubmed: 2415587
Cancer Discov. 2016 Mar;6(3):247-55
pubmed: 26715643
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397
Breast Cancer Res Treat. 2012 Jun;133(3):979-95
pubmed: 22119938
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Discov. 2016 Mar;6(3):270-85
pubmed: 26715645
Lab Invest. 2009 Mar;89(3):301-14
pubmed: 19139719
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Oncology. 2005;68(2-3):97-106
pubmed: 15886501
Neoplasia. 2015 Sep;17(9):735-741
pubmed: 26476081
Oncotarget. 2016 Nov 8;7(45):72819-72832
pubmed: 27637082
Int J Cancer. 1983 Jan 15;31(1):13-20
pubmed: 6339421
BMC Cancer. 2012 Apr 03;12:134
pubmed: 22471961